NCT06830343View on ClinicalTrials.gov

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

PHASE1RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

October 1, 2026

Conditions
Overweight or Obesity
Interventions
DRUG

SYH9017

subcutaneous injection once time in SAD and four times in MAD

DRUG

Placebo

subcutaneous injection once time in SAD and four times in MAD

DRUG

Wegovy ®

subcutaneous injection once a week

Trial Locations (1)

Unknown

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY